May 16, 2014 10:40 AM EDT
FDA Rejects Novartis’ Heart Failure Drug--Again
Novartis’ experimental heart failure drug, Serelaxin, was yet again rejected by the U.S. Food and Drug Administration after undergoing another trial to prove its effectiveness and ability to improve symptoms in patients.